Basal forebrain and saporin cholinergic lesions: the devil dwells in delivery details.
Kalinchuk
Anna V
AV
Porkka-Heiskanen
Tarja
T
McCarley
Robert W
RW
D000241:Adenosine / Q000378:metabolism*; D000818:Animals; D000911:Antibodies, Monoclonal; D018678:Cholinergic Agents; D002799:Cholinergic Fibers / Q000502:physiology*; D006706:Homeostasis / Q000502:physiology*; D006801:Humans; D000922:Immunotoxins; D007276:Injections, Intraventricular; D009699:N-Glycosyl Hydrolases; D009434:Neural Pathways / Q000502:physiology; D009474:Neurons / Q000502:physiology; D016548:Prosencephalon / Q000502:physiology*; D051381:Rats; D043682:Receptor, Adenosine A1 / Q000502:physiology; D043705:Receptor, Adenosine A2A / Q000502:physiology; D054789:Ribosome Inactivating Proteins, Type 1; D000076985:Saporins; D012890:Sleep / Q000502:physiology*
C085696:192 IgG-saporin; D000911:Antibodies, Monoclonal; D018678:Cholinergic Agents; D000922:Immunotoxins; D043682:Receptor, Adenosine A1; D043705:Receptor, Adenosine A2A; D054789:Ribosome Inactivating Proteins, Type 1; D009699:N-Glycosyl Hydrolases; D000076985:Saporins; D000241:Adenosine